Next Article in Journal
A Case for Incidental Coronary Angiography During Percutaneous Closure of the Patent Foramen Ovale?
Previous Article in Journal
How to Transform You into a Radialist: Literature Review
 
 
Cardiovascular Medicine is published by MDPI from Volume 28 Issue 1 (2025). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with Editores Medicorum Helveticorum (EMH).
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Review

Prevalence, Mechanism and Management of Atrial Fibrillation in Athletes †

1
horax Institute, Hospital Clínic, University of Barcelona, Institut d’Investigació Biomèdica August Pi i Sunyer (IDIBAPS), Barcelona, Spain
2
Thorax Institute (ICT)—Cardiology Department, Hospital Clinic, University of Barcelona, Villarroel 170, 08036 ES-Barcelona, Catalonia, Spain
*
Author to whom correspondence should be addressed.
Lecture at the annual meeting of the Swiss Society of Cardiology, Swiss Society of Sports medicine, Swiss Society of Paediatric Cardiology, Swiss Society of Thoracic and Cardiovascular Surgery and the Swiss Society of Hypertension; Basle, June 8–6, 2011.
Cardiovasc. Med. 2011, 14(10), 271; https://doi.org/10.4414/cvm.2011.01617
Submission received: 26 July 2011 / Revised: 26 August 2011 / Accepted: 26 September 2011 / Published: 26 October 2011

Summary

Atrial fibrillation (AF) is the most commonly encountered arrhythmia in clinical practice with an estimated prevalence of 0.4% to 1% in the general population [1], increasing with age to 8% in those older than 80 years [2]. The recognised risk factors for developing AF include age, structural heart disease, hypertension, diabetes mellitus and hyperthyroidism [3]. However, the mechanisms underlying the onset and maintenance of AF in patients younger than 60 years in whom no cardiovascular disease or any other known causal factor is present are yet to be clarified. This condition is termed lone AF [4], and may be responsible for as many as 30% of patients with paroxysmal AF seeking medical attention [5,6].
It is well known that regular exercise is beneficial to health and reduces the risks of cardiovascular diseases [7,8]. However, recent studies suggest that longterm endurance exercise may increase the incidence of AF [9,10,11,12,13,14,15,16].
This review article is intended to analyse the possible links between AF and endurance sport practice, the pathophysiological mechanisms responsible for this association and the recommended therapeutic options.

Atrial fibrillation and endurance sport

In recent years, an association has been demonstrated between endurance sport practice and AF or atrial flutter (Figure 1). In 1998, Karjalainen et al. [9] evaluated the presence of AF in 228 veteran male orienteering racers (cross-country runners) and compared this with AF prevalence in a matched control group. Lone AF (LAF) was diagnosed in 12 orienteering racers (5.3%) vs. 2 control subjects (0.9%). A retrospective analysis of our group including 1160 consecutive patients showed that the proportion of regular sport practice (defined as a high-intensity sport practice of at least three hours a week) among men with LAF was much higher than among men from the general population (63 vs. 15%) [10]. An age-matched case-control study of the same population of LAF patients found that the risk of developing LAF was five times greater (OR 5.06 [1.35–19]) in those currently practicing an endurance sport [11], and this association was observed at more than 1500 lifetime hours of sport practice. In a further study, our group analysed the incidence of LAF among marathon runners. The study included 183 individuals who ran the Barcelona Marathon in 1992 and 290 sedentary healthy individuals. After ten years of follow-up, the incidence of LAF was higher among marathon runners compared to sedentary men (annual incidence: 0.43/100 for runners, 0.11/100 for sedentary men) [15].
Heidbuchel et al. [13] evaluated the influence of sport activity on the risk of AF after the ablation of atrial flutter. Of 137 patients with atrial flutter undergoing ablation of the right atrial isthmus, 31 (23%) regularly participated in endurance sports. A history of competitive sport practice was associated with a higher postablation risk of developing AF (multivariate HR 1.81 [1.10–2.98, p = 0.02]), and ongoing practice of an endurance sport after the ablation also increased the risk of AF (multivariate HR 1.68 [0.92–3.06], p = 0.08).
Baldesberger et al. [12] published similar data in a study of 62 professional cyclists who completed the Tour de Suisse professional cycling race at least once during the years 1955–1975. These athletes were compared with a control group of 62 male golfers who had never performed high endurance training. Individuals were matched for age, weight, hypertension and cardiac medication. Paroxysmal or persistent AF or atrial flutter was reported more often in the cyclists.
Additionally, recently, Aizer et al. [17] investigated the relation of vigorous exercise to AF risk in a large cohort of healthy male physicians. The authors compared four exercising groups with increasing levels of endurance with a non-exercising group as reference. The multivariate analysis at three-year follow-up showed that there was an increased risk of AF in the most exercising group. The increase in risk decreased with increasing age. In men >50 years of age, no significant association was found. However, the risk remained statistically significantly higher in men <50 years of age and joggers.
In contrast with these previous studies, Pellicia et al. [18] reported that LAF was uncommon among competitive athletes and the incidence was similar to that observed in the general population. However, it should be noted that this study was performed among young athletes at the height of their activity, while previous studies supporting the association have included middle-aged individuals, after many years of sport practice. On the other hand, in the Cardiovascular Health Study [19], the incidence of AF in older adults (>65 years old) was lower with moderate-intensity exercise. However, this was not true with high-intensity exercise.
In summary, most of the available data support the significant association between excessive sport practice and the occurrence of lone AF. However, the underlying mechanisms are a matter of debate.
Finally, it should be mentioned that most of the previous studies have been performed in men, whereas the risk for women has not been well investigated.

Pathophysiology of AF in endurance athletes

The pathophysiological mechanisms underlying the increased risk of AF in individuals who practice an endurance sport remain unclear. Several mechanisms may be acting together. It is well accepted that arrhythmias depend on triggers, substrates and modulators and these factors might be present in relation to physical activity.

Triggers: role of atrial ectopy

Pulmonary vein ectopy has been shown to be the trigger in most episodes of paroxysmal AF [20]. Both atrial and ventricular ectopy have been shown to be increased as a consequence of physical activity [12,21]. Therefore, increased atrial ectopy, acting upon an appropriate substrate, might explain the increased risk for AF associated with sport practice. However, although an increase in ventricular ectopy and VT runs in former professional cyclists was reported by Baldesberger et al. [12], they did not find an increased incidence of atrial ectopy. Therefore, there is no currently available data to confirm the role of atrial ectopy as AF trigger in athletes.

Influence of the autonomic nervous system

The role of the cardiac autonomic nervous system (ANS) in the initiation and maintenance of AF has been actively investigated [22,23,24,25]. Coumel [26] studied the influence of autonomic innervations in the appearance of AF and atrial flutter and originally described “vagal AF”. The symptoms of “vagal AF” described by Coumel include: (1.) predominantly affects males between 30 and 50 years of age, (2.) usually occurs at night and rarely occurs between breakfast and lunch when the sympathetic tone is high, (3.) rarely occurs during exercise or emotional stress, (4.) is frequently triggered during relaxation after stress and (5.) is often preceded by bradycardia lasting from seconds to hours. However, he did not establish a relationship between these episodes of AF and sport practice.
In addition, experimental animal models have demonstrated that atrial fibrillation can be induced by acetylcholine [27] and that increasing vagal tone shortens the atrial refractory period, which, combined with atrial stimulation, induces AF [28].
High vagal tone manifesting as sinus bradycardia and asymptomatic AV conduction delay in well-trained athletes has been known for decades. According to the GIRAFA study [14], vagal AF is the rule rather than the exception in patients with lone AF (70% of consecutive patients with lone AF had vagal AF). Therefore, the increased vagal tone induced by endurance sport practice could facilitate the appearance of AF. Further studies with a systematic inquiry into AF origin are needed.

Exercise and structural changes in the atrium

Long-term endurance sport practice has been proposed as being responsible for structural changes in the atrium (e.g., enlargement, fibrosis) that may create a favourable substrate for the disease, similar to hypertension or structural heart disease as a consequence of chronic volume and pressure overload. A small study by Frustaci et al. [29] analysed the structural changes in the atria of patients with lone AF. Inflammatory lymphomonuclear infiltrates, compatible with myocarditis, were found in 66% of the patients, a non-inflammatory cardiomyopathic process in 17% and patchy fibrosis in the remaining 17%.
Recent experimental data from our group showed that endurance exercise may induce fibrosis in a rat model of chronic exercise, particularly at the atrial and right ventricular level [30]. In this study, an increase in mRNA and protein expression of a series of fibrotic markers in the RV and in both atria was showed at 16 weeks of training. Additionally, Lindsay and Dunn [31] showed an increase in humoral markers of fibrosis in veteran athletes compared to sedentary subjects. Athletes showed an increase in three collagen markers—plasma PICP, CITP, and TIMP-1—when compared with sedentary controls, suggesting that long-term sport practice may provoke fibrosis as part of the hypertrophic process in veteran athletes.
More recently, Breuckmann et al. [32] compared the myocardial distribution of late gadolinium enhancement (LGE) with delayed-enhancement cardiac MR imaging in nonprofessional male marathon runners and in asymptomatic control subjects and found a higher prevalence of LGE in runners than in agematched control subjects (12% vs. 4%; p = 0.077). Similarly, Wilson et al. [33] observed a high prevalence (50%) of myocardial fibrosis in healthy, asymptomatic, veteran, male life-long athletes, compared to zero cases in age-matched veteran controls and young athletes.
Additionally, previous studies have found that excessive training may lead to tissue injury, which activates circulating monocytes, producing large quantities of IL-1β and/or IL-6 and/or TNF-α and systemic inflammation [34].
However, there are no studies in the literature that confirm an association between AF, inflammation and exercise.
Recent studies suggest that structural remodelling is often present in the atrium of elite athletes. Pelliccia et al. [17] described the remodelling induced by exercise in elite sport athletes. Their study showed that those involved in regular endurance practice have a larger atrium than the sedentary controls. Furthermore, a significant proportion (20%) had enlarged atria according to established normal values.
GIRAFA study data [14] found that patients with LAF had a larger atrium than the controls, and patients with a first episode of AF had the same atrial size compared to those suffering recurrences, which might mean that structural changes were present before onset of AF.
In addition, experimental studies of our group [30] observed a left atrial dilatation, LV hypertrophy and dilatation, and diastolic dysfunction at 16 weeks of training, findings which are consistent with the features of the athlete’s heart described in humans.
The reversibility of arrhythmogenic remodelling has also been assessed. Clinical studies have reported regression of the morphological changes characteristic of the athlete’s heart after long-term detraining [35]. Our group evaluated whether a period of rest could allow reversion of the profibrotic changes induced by endurance training in our model of endurance exercise in rats [30]. After eight weeks of detraining, the abnormal cardiac remodelling parameters resulting from intense exercise training regressed to control levels.
More studies are needed to ascertain the mechanisms that participate in the promotion and reversal of the remodelling associated with long-term exercise and detraining, respectively.

Clinical characteristics of sport-related atrial fibrillation

Whereas AF is an unusual finding in athletes below 35 years old, it becomes more common after 45 years of age. The typical clinical profile of sport-related AF is a veteran male athlete in his forties or fifties, who has been involved in regular endurance sport practice since his youth and is currently involved in regular endurance high-intensity sport practice.
The AF is usually paroxysmal with crisis, initially very occasional and self-limited, but typically becomes more frequent and prolonged over the years as AF becomes persistent. The AF crisis frequently coexists with common atrial flutter in many patients. Characteristically, AF episodes occur at night or after meals. Since the AF crisis rarely occurs during exercise, the patient is reluctant to accept a relationship between the arrhythmia and sport practice.

Management of AF in athletes

Furlanello et al. [35] described a good response to sport abstinence in top level athletes with AF. Hoogsteen J et al. [36] showed that 11–30% athletes experienced reduction of attacks of AF by reducing sport activity. Our observations agree with these findings, so our first approach in these patients is to recommend limiting physical activity. However, these patients are very dependent on physical activity and it is difficult for them to reduce their endurance sport practice.
After all of the potential contributing factors have been eliminated (i.e., medical conditions such as hyperthyroidism, pericarditis, Wolff-Parkinson-White syndrome, hypertrophic cardiomyopathy or long QT syndrome; substances such as cocaine, caffeine, anabolic steroids and sympathomimetics in cold medicines), the Study Group on Sports Cardiology of the European Association for Cardiovascular Prevention and Rehabilitation [37] recommends that athletes in an early stage of paroxysmal AF should discontinue training for two months to stabilise sinus rhythm. The degree of improvement during this resting period determines if athletes can resume their training.
In athletes without other cardiac disorders, the recommendation for sport participation also depends on the ventricular rate during AF. If there is a history of high ventricular rate or haemodynamic instability during AF, the athletes should be instructed to stop exercising if palpitation or related symptoms occur. Such patients may need medications that slow the ventricular rate, ideally at doses that do not cause sinus bradycardia at rest or chronotropic incompetence during exercise. In these patients, we prescribe AV-node slowing agents despite moderate bradycardia during sinus rhythm. A close follow-up including ECG-Holter monitoring to rule out severe bradycardia is usually performed.
Task Force 7 of the 36th Bethesda Conference [38] recommends that athletes with asymptomatic AF in the absence of structural heart disease can be permitted to participate in any competitive sport, provided they maintain a ventricular rate that increases and slows appropriately and is comparable to that of a normal sinus response in relation to the level of activity, while receiving no therapy or therapy with AV nodalblocking drugs. Asymptomatic athletes who have AF episodes lasting 5 to 15 s with no increase in duration during exercise can participate in all sports.
The possible long-term role of medications (ACE inhibitors, angiotensin inhibitors, calcium antagonists or beta-blockers) in preventing cardiac hypertrophy remains to be elucidated, although angiotensin inhibitors do seem to play a role in improving the results of cardioversion or AF ablation [39,40]. Particular caution should be exercised with the monotherapeutic use of class 1 antiarrhythmic drugs in AF patients. These drugs may prevent AF recurrences, but can also convert AF into slow atrial flutter, which may conduct oneto-one to the ventricles during situations of high sympathetic tone [41,42]. Class 1 drugs can be initiated for the prevention of AF episodes after adequate ventricular rate control during exercise has been assured.
When therapy with class 1 drugs is indicated in athletes, a combination with diltiazem or prophylactic ablation of the flutter circuit must be considered. The “hybrid” therapy of class 1 drugs and the ablation of flutter may obviate the need for maintenance therapy with bradycardic agents [43,44].
In most athletes with paroxysmal AF we use class 1 drugs as the “pill-in-the pocket” approach [45]. These patients are always instructed to refrain from sports as long as the arrhythmia persists and until at least one half-life of the antiarrhythmic drug has passed.
On the other hand, circumferential pulmonary vein ablation (CPVA) is an effective and safe treatment of AF, with success rates ranging from 40% to 85% in the general population [46]. In athletes, a study by Furlanello et al. [47] described a 90–success after a mean of two ablation procedures in 20 athletes without major complications.
A recent study by our group [48] compared the effectiveness of CPVA between a population of endurance athletes with lone AF and other patients with AF. Athletes were defined as those who performed regular endurance sport activity (cycling, jogging, swimming, soccer, rowing, etc.) for at least three hours per week for at least the 10 years immediately preceding the arrhythmia diagnosis. The mean age of endurance athletes with lone AF was 48.5 years and 93% were male. In all the patients CPVA was performed due to symptomatic and drug-refractory AF. We did not find differences in CPVA effectiveness between the two groups (Figure 2). Furthermore, endurance sport practice was not a predictor of the ablation outcome.
Anticoagulation may be necessary in competitive and leisure time athletes with unsuccessful rhythm control or with rate control treatment, depending on the presence of classic risk factors for thromboembolic events [49]. Anticoagulation therapy excludes these individuals from sports with a risk of bodily collision or trauma [37].
In summary, endurance sport cessation associated with drug therapy seems to us the best suitable approach as an initial therapy, particularly in nonprofessional, veteran athletes. However, based on the excellent results of AF ablation in this group of patients, we offer them an early ablation management, which is also offered to patients reluctant to take drugs.

Conclusions

Long-term endurance sport practice has been demonstrated to increase the risk for AF, probably due to the underlying role of cardiac autonomic nervous system and left atrial structural changes (dilatation, inflammation and fibrosis). Further studies are needed to clarify the mechanism of AF in endurance sport practice and to look for a threshold limit for the intensity and duration of physical activity that may avoid the development of AF, without limiting the cardiovascular benefits of exercise.

Funding

This research received no external funding.

Conflicts of Interest

The authors declare no conflicts of interest.

References

  1. Go, A.S.; Hylek, E.M.; Phillips, K.A.; Chang, Y.; Henault, L.E.; Selby, J.V.; et al. Prevalence of diagnosed atrial fibrillation in adults: National implications for rhythm management and stroke prevention: The AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA. 2001, 285, 2370–5. [Google Scholar] [CrossRef]
  2. Furberg, C.D.; Psaty, B.M.; Manolio, T.A.; Gardin, J.M.; Smith, V.E.; Rautaharju, P.M. Prevalence of atrial fibrillation in elderly subjects (the Cardiovascular Health Study). Am J Cardiol. 1994, 74, 236–41. [Google Scholar] [CrossRef]
  3. Benjamin, E.J.; Wolf, P.A.; D’Agostino, R.B.; Silbershatz, H.; Kannel, W.B.; Levy, D. Impact of atrial fibrillation on the risk of death: The Framingham Heart Study. Circulation. 1998, 98, 946–52. [Google Scholar] [CrossRef]
  4. Fuster, V.; Rydén, L.E.; Cannom, D.S.; Crijns, H.J.; Curtis, A.B.; Ellenbogen, K.A.; et al. ACC/AHA/ESC 2006 Guidelines for the Management of Patients with Atrial Fibrillation—Executive Summary. A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation). J Am Coll Cardiol. 2006, 48, 854–906. [Google Scholar]
  5. Planas, F.; Romero-Menor, C.; Vázquez-Oliva, J.S.G.; Poblet, T.; Navarro-López, F., on behalf of the FAP Study researchers. Perfil clínico de la fibrilación auricular paroxística primaria (registro FAP). Rev Esp Cardiol. 2001, 54, 838–44. [Google Scholar] [CrossRef] [PubMed]
  6. Lévy, S.; Maarek, M.; Coumel, P.; Guize, L.; Lekieffre, J.; Medvedowsky, J.L.; et al. Characterization of different subsets of atrial fibrillation in general practice in France: The ALFA study. The College of French Cardiologists. Circulation. 1999, 99, 3028–35. [Google Scholar] [CrossRef] [PubMed]
  7. Morris, J.N.; Everitt, M.G.; Pollard, R.; Chave, S.P.; Semmence, A.M. Vigorous exercise in leisure-time: Protection against coronary heart disease. Lancet. 1980, 2, 1207–10. [Google Scholar] [CrossRef]
  8. Kujala, U.M.; Kaprio, J.; Taimela, S.; Sarna, S. Prevalence of diabetes, hypertension, and ischemic heart disease in former elite athletes. Metabolism. 1994, 43, 1255–60. [Google Scholar] [CrossRef] [PubMed]
  9. Karjalainen, J.; Kujala, U.M.; Kaprio, J.; Sarna, S.; Viitasalo, M. Lone atrial fibrillation in vigorously exercising middle aged men: Case-control study. BMJ. 1998, 316, 1784–5. [Google Scholar] [CrossRef]
  10. Mont, L.; Sambola, A.; Brugada, J.; Vacca, M.; Marrugat, J.; Elosua, R.; et al. Long lasting sport practice and atrial fibrillation. Eur Heart J. 2002, 23, 477–82. [Google Scholar] [CrossRef]
  11. Elosua, R.; Arquer, A.; Mont, L.; Sambola, A.; Molina, L.; Garcia-Moran, E.; et al. Sport practice and the risk of lone atrial fibrillation: A case-control study. Int J Cardiol. 2005, 108, 332–7. [Google Scholar] [CrossRef]
  12. Baldesberger, S.; Bauersfeld, U.; Candinas, R.; Seifert, B.; Zuber, M.; Ritter, M.; et al. Sinus node disease and arrhythmias in the long term followup of former professional cyclists. Eur Heart J. 2008, 29, 71–8. [Google Scholar] [CrossRef]
  13. Heidbuchel, H.; Anne, W.; Willems, R.; Adriaenssens, B.; Van de Werf, F.; Ector, H. Endurance sport is a risk factor for atrial fibrillation after ablation for atrial flutter. Int J Cardiol. 2006, 107, 67–72. [Google Scholar] [CrossRef]
  14. Mont, L.; Tamborero, D.; Elosua, R.; Molina, I.; Coll-Vinent, B.; Sitges, M.; et al. on behalf of the GIRAFA (Grup Integrat de Recerca en Fibril-lacio Auricular) Investigators. Physical activity, height and left atrial size are independent risk factors for lone atrial fibrillation in middle-aged healthy individuals. Europace. 2008, 10, 15–20. [Google Scholar] [CrossRef]
  15. Molina, L.; Mont, L.; Marrugat, J.; Berruezo, A.; Brugada, J.; Bruguera, J.; et al. Long-term endurance sport practice increases the incidence of lone atrial fibrillation in men: A follow-up study. Europace. 2008, 10, 618–23. [Google Scholar] [CrossRef]
  16. Abdulla, J.; Nielsen, J.R. Is the risk of atrial fibrillation higher in athletes than in the general population? A systematic review and meta-analysis. Europace. 2009, 11, 1156–9. [Google Scholar] [CrossRef]
  17. Aizer, A.; Gaziano, J.M.; Cook, N.R.; Manson, J.E.; Burimg, J.E.; Albert, C. Aizer A, Gaziano JM; et al. Relation of vigorous exercise to risk of atrial fibrillation. Am J Cardiol. 2009, 103, 1572–1577e7. [Google Scholar] [CrossRef] [PubMed]
  18. Pelliccia, A.; Maron, B.J.; Di Paolo, F.M.; Biffi, A.; Quattrini, F.M.; Pisicchio, C.; et al. Prevalence and clinical significance of left atrial remodelling in competitive athletes. J Am Coll Cardiol. 2005, 46, 690–6. [Google Scholar] [CrossRef] [PubMed]
  19. Mozaffarian, D.; Furberg, C.D.; Psaty, B.M.; Siscovick, D. Physical activity and incidence of atrial fibrillation in older adults. The Cardiovascular Health Study. Circulation. 2008, 118, 800–7. [Google Scholar] [CrossRef] [PubMed]
  20. Haissaguerre, M.; Jais, P.; Shah, D.C.; Takahashi, A.; Hocini, M.; Quiniou, G.; et al. Spontaneous initiation of atrial fibrillation by ectopic beats originating in the pulmonary veins. N Engl J Med. 1998, 339, 659–66. [Google Scholar] [CrossRef]
  21. Bjornstad, H.; Storstein, L.; Meen, H.D.; Hals, O. Ambulatory electrocardiographic findings in top athletes, athletic students and control subjects. Cardiology. 1994, 84, 42–50. [Google Scholar]
  22. Bettomi, M.; Zimmermann, M. Autonomic Tone Variations Before the Onset of Paroxysmal Atrial Fibrillation. Circulation. 2002, 105, 2753–9. [Google Scholar] [CrossRef]
  23. Amar, D.; Zhang, H.; Miodownik, S.; Kadish, A.H. Competing Autonomic Mechanisms Precede the Onset of Postoperative Atrial Fibrillation. JACC. 2003, 42, 1262–70. [Google Scholar] [CrossRef]
  24. Ogawa, M.; Zhou, S.; Tan, A.Y.; et al. Left stellate ganglion and vagal nerve activity and cardiac arrhythmias in ambulatory dogs with pacing-induced congestive heart failure. J Am Coll Cardiol. 2007, 50, 335–43. [Google Scholar] [CrossRef] [PubMed]
  25. Patterson, E.; Po, S.S.; Scherlag, B.J.; Lazzara, R. Triggered firing in pulmonary veins initiated by in vitro autonomic nerve stimulation. Heart Rhythm. 2005, 2, 632–3. [Google Scholar] [CrossRef] [PubMed]
  26. Coumel, P. Paroxysmal atrial fibrillation: A disorder of autonomic tone? Eur Heart J. 1994, 15, 9–16. [Google Scholar] [CrossRef]
  27. Hoff, H.E.; Geddes, L.A. Cholinergic factor in atrial fibrillation. J Appl Physiol. 1955, 8, 177–92. [Google Scholar] [CrossRef] [PubMed]
  28. Alessie, R.; Nusynowitz, M.; Abildskow, J.; Moe, G.K. Non-uniform distribution of vagal effects on the atrial refractory period. Am J Physiol. 1958, 194, 406–10. [Google Scholar] [CrossRef]
  29. Frustaci, A.; Chimenti, C.; Bellocci, F.; Morgante, E.; Russo, M.A.; Maseri, A. Histological substrate of atrial biopsies in patients with lone atrial fibrillation. Circulation. 1997, 96, 1180–4. [Google Scholar] [CrossRef]
  30. Benito, B.; Gay-Jordi, G.; Serrano, A.; Guasch, E.; Shi, Y.; Tardif, J.C.; et al. Cardiac Arrhythmogenic Remodeling in a Rat Model of Long-Term Intensive Exercise Training. Circulation. 2011, 123, 13–22. [Google Scholar] [CrossRef]
  31. Lindsay, M.M.; Dunn, F.G. Biochemical evidence of myocardial fibrosis in veteran endurance athletes. Br J Sports Med. 2007, 41, 447e52. [Google Scholar] [CrossRef]
  32. Breuckmann, F.; Möhlenkamp, S.; Nassenstein, K.; Lehmann, N.; Ladd, S.; Schmermund, A.; et al. Myocardial Late Gadolinium Enhancement: Prevalence, Pattern, and Prognostic Relevance in Marathon Runners. Radiology. 2009, 251, 50–7. [Google Scholar] [CrossRef]
  33. Wilson, M.; O’Hanlon, R.; Prasad, S.; Deighan, A.; MacMillan, P.; Oxboroughet, D.; et al. Diverse patterns of myocardial fibrosis in lifelong, veteran endurance athletes. J Appl Physiol. 2011, 110, 1622–6. [Google Scholar] [CrossRef]
  34. Smith, L.L. Cytokine hypothesis of overtraining: A physiological adaptation to excessive stress? Med Sci Sports Exerc. 2000, 32, 317–31. [Google Scholar] [CrossRef]
  35. Furlanello, F.; Bertoldi, A.; Dallago, M.; Galassi, A.; Fernando, F.; Biffi, A.; et al. Atrial fibrillation in elite athletes. J Cardiovasc Electrophysiol. 1998, 9, S63–8. [Google Scholar] [PubMed]
  36. Hoogsteen, J.; Schep, G.; van Hemel, N.M.; van der Wall, E.E. Paroxysmal atrial fibrillation in male endurance athletes. A 9-year follow up. Europace. 2004, 6, 222–8. [Google Scholar] [CrossRef]
  37. Heidbuchel, H.; Panhuyzen-Goedkoop, N.; Corrado, D.; et al. Recommendations for participation in leisure-time physical activity and competitive sports in patients with arrhythmias and potentially arrhythmogenic conditions Part I: Supraventricular arrhythmias and pacemakers. Eur J Cardiovasc Prev Rehabil. 2006, 13, 475–84. [Google Scholar] [CrossRef] [PubMed]
  38. Zipes, D.P.; Ackerman, M.J.; Estes, M.; Grant, A.O.; Merburg, R.J.; Van Hare, G. Eligibility recommendations for competitive athletes with cardiovascular abnormalities—General considerations. Task Force 7: Arrhythmia. J Am Coll Cardiol. 2005, 45, 1354–63. [Google Scholar] [CrossRef] [PubMed]
  39. Anne, W.; Willems, R.; Van der, M.N.; Van de, W.F.; Ector, H.; Heidbuchel, H. Atrial fibrillation after radiofrequency ablation of atrial flutter: Preventive effect of angiotensin converting enzyme inhibitors, angiotensin II receptor blockers, and diuretics. Heart. 2004, 90, 1025–30. [Google Scholar] [CrossRef]
  40. Madrid, A.H.; Bueno, M.G.; Rebollo, J.M.; Marin, I.; Pena, G.; Bernal, E.; et al. Use of irbesartan to maintain sinus rhythm in patients with long-lasting persistent atrial fibrillation: A prospective and randomized study. Circulation. 2002, 106, 331–6. [Google Scholar] [CrossRef]
  41. Kawabata, M.; Hirao, K.; Horikawa, T.; Suzuki, K.; Motokawa, K.; Suzuki, F.; et al. Syncope in patients with atrial flutter during treatment with class Ic antiarrhythmic drugs. J Electrocardiol. 2001, 34, 65–72. [Google Scholar] [CrossRef] [PubMed]
  42. Brembilla-Perrot, B.; Houriez, P.; Beurrier, D.; Claudon, O.; Terrier de la Chaise, A.; Louis, P. Predictors of atrial flutter with 1:1 conduction in patients treated with class I antiarrhythmic drugs for atrial tachyarrhythmias. Int J Cardiol. 2001, 80, 7–15. [Google Scholar] [CrossRef] [PubMed]
  43. Nabar, A.; Rodriguez, L.M.; Timmermans, C.; van den Dool, A.; Smeets, J.L.; Wellens, H.J. Effect of right atrial isthmus ablation on the occurrence of atrial fibrillation: Observations in four patient groups having type I atrial flutter with or without associated atrial fibrillation. Circulation. 1999, 99, 1441–5. [Google Scholar] [CrossRef]
  44. Reithmann, C.; Dorwarth, U.; Dugas, M.; Hahnefeld, A.; Ramamurthy, S.; Remp, T.; et al. Risk factors for recurrence of atrial fibrillation in patients undergoing hybrid therapy for antiarrhythmic drug-induced atrial flutter. Eur Heart J. 2003, 24, 1264–72. [Google Scholar] [CrossRef]
  45. Alboni, P.; Botto, G.L.; Baldi, N.; Luzi, M.; Russo, V.; Gianfranchi, L.; et al. Outpatient treatment of recent-onset atrial fibrillation with the ‘‘pill-inthe-pocket’’ approach. N Engl J Med. 2004, 351, 2384–91. [Google Scholar] [CrossRef]
  46. Cappato, R.; Calkins, H.; Chen, S.A.; Davies, W.; Iesaka, Y.; Kalman, J.; et al. Worldwide survey on the methods, efficacy, and safety of catheter ablation for human atrial fibrillation. Circulation. 2005, 111, 1100–5. [Google Scholar] [CrossRef]
  47. Furlanello, F.; Lupo, P.; Pittalis, M.; Foresti, S.; Vitali-Serdoz, L.; Francia, P.; et al. Radiofrequency catheter ablation of atrial fibrillation in athletes referred for disabling symptoms preventing usual training schedule and sport competition. J Cardiovasc Electrophysiol. 2008, 19, 457–62. [Google Scholar] [CrossRef]
  48. Calvo, N.; Mont, L.; Tamborero, D.; Berruezo, A.; Viola, G.; Guasch, E.; et al. Efficacy of circumferential pulmonary vein ablation of atrial fibrillation in endurance athletes. Europace. 2010, 12, 30–6. [Google Scholar] [CrossRef]
  49. Reynolds, M.W.; Fahrbach, K.; Hauch, O.; Wygant, G.; Estok, R.; Cella, C.; et al. Warfarin anticoagulation and outcomes in patients with atrial fibrillation: A systematic review and metaanalysis. Chest. 2004, 126, 1938–45. [Google Scholar] [CrossRef] [PubMed]
Figure 1. Meta-analysis of AF risk in athletes compared with controls. From: Abdulla J, Nielsen JR. Is the risk of atrial fibrillation higher in athletes than in the general population? Europace. 2009;11:1156–9. © Oxford University Press, Oxford, UK. Reprint with permission.
Figure 1. Meta-analysis of AF risk in athletes compared with controls. From: Abdulla J, Nielsen JR. Is the risk of atrial fibrillation higher in athletes than in the general population? Europace. 2009;11:1156–9. © Oxford University Press, Oxford, UK. Reprint with permission.
Cardiovascmed 14 00271 g001
Figure 2. Kaplan-Meier curves for long-term freedom from recurrent arrhythmias after a single ablation procedure in lone AF athletes group (dashed line) and control group (solid line). From: Calvo N, Mont L, Tamborero D, Berruezo A, Viola G, Guasch E, et al. Efficacy of circumferential pulmonary vein ablation of atrial fibrillation in endurance athletes. Europace. 2010;12(1):30–6. © Oxford University Press, Oxford, UK. Reprint with permission.
Figure 2. Kaplan-Meier curves for long-term freedom from recurrent arrhythmias after a single ablation procedure in lone AF athletes group (dashed line) and control group (solid line). From: Calvo N, Mont L, Tamborero D, Berruezo A, Viola G, Guasch E, et al. Efficacy of circumferential pulmonary vein ablation of atrial fibrillation in endurance athletes. Europace. 2010;12(1):30–6. © Oxford University Press, Oxford, UK. Reprint with permission.
Cardiovascmed 14 00271 g002

Share and Cite

MDPI and ACS Style

Calvo, N.; Mont, L. Prevalence, Mechanism and Management of Atrial Fibrillation in Athletes. Cardiovasc. Med. 2011, 14, 271. https://doi.org/10.4414/cvm.2011.01617

AMA Style

Calvo N, Mont L. Prevalence, Mechanism and Management of Atrial Fibrillation in Athletes. Cardiovascular Medicine. 2011; 14(10):271. https://doi.org/10.4414/cvm.2011.01617

Chicago/Turabian Style

Calvo, Naiara, and Lluís Mont. 2011. "Prevalence, Mechanism and Management of Atrial Fibrillation in Athletes" Cardiovascular Medicine 14, no. 10: 271. https://doi.org/10.4414/cvm.2011.01617

APA Style

Calvo, N., & Mont, L. (2011). Prevalence, Mechanism and Management of Atrial Fibrillation in Athletes. Cardiovascular Medicine, 14(10), 271. https://doi.org/10.4414/cvm.2011.01617

Article Metrics

Back to TopTop